2 most recent filings and news items mentioning LFMD. Updated every 60 seconds.
EarningsAug 5, 2026Positive
The company reported $47.3 million in revenue and a gross margin expansion to 89% as it transitions to branded GLP-1 therapies, while reiterating expectations for a return to positive adjusted EBITDA in the second half of 2026.
View filing at SEC.gov →
OtherJun 22, 2026Positive
LifeMD announced an exclusive collaboration with Antares Pharma to offer a direct-to-patient self-pay program for XYOSTED testosterone injection, launching in 37 states at $249/month including care and medication. The partnership leverages LifeMD's virtual care platform and pharm
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.